Legend Biotech (LEGN) Free Cash Flow (2019 - 2025)
Legend Biotech (LEGN) posted Free Cash Flow of -$12.2 million for Q4 2025, down 136.09% on a QoQ basis from $33.8 million in Q3 2025, and up 88.7% year-over-year from -$6.5 million in Q4 2024.
Legend Biotech (LEGN) has 7 years of Free Cash Flow data on file, last reported at -$12.2 million in Q4 2025.
- In Q4 2025, Free Cash Flow rose 88.7% year-over-year to -$12.2 million; the TTM figure through Dec 2025 stood at -$84.0 million (up 46.91% YoY), while the FY2025 annual figure was -$100.2 million, up 36.62% from the prior year.
- Free Cash Flow eased to -$12.2 million in Q4 2025, from $33.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $33.8 million in Q3 2025 and bottomed at -$156.3 million in Q4 2021.
- A 5-year average of -$53.3 million and a median of -$49.8 million in 2021 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow plunged 8513.94% — and 2025, when it jumped 145.83%.
- Year by year, Free Cash Flow stood at -$156.3 million in 2021, then soared by 81.56% to -$28.8 million in 2022, then slumped by 356.25% to -$131.5 million in 2023, then gained by 17.9% to -$107.9 million in 2024, then jumped by 88.7% to -$12.2 million in 2025.
- The last three Free Cash Flow figures came in at -$12.2 million (Q4 2025), $33.8 million (Q3 2025), and -$3.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -354.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.20 Mn |
| Dec 31, 2025 | -12.20 Mn |
| Sep 30, 2025 | 33.81 Mn |
| Sep 30, 2025 | 33.81 Mn |
| Jun 30, 2025 | -3.82 Mn |
| Jun 30, 2025 | -3.82 Mn |
| Mar 31, 2025 | -101.75 Mn |
| Mar 31, 2025 | -101.75 Mn |
| Dec 31, 2024 | -107.93 Mn |
| Dec 31, 2024 | -107.93 Mn |
| Sep 30, 2024 | -73.76 Mn |
| Sep 30, 2024 | -73.76 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Jun 30, 2024 | 1.77 Mn |
| Mar 31, 2024 | 21.76 Mn |
| Mar 31, 2024 | 21.76 Mn |
| Dec 31, 2023 | -131.47 Mn |
| Dec 31, 2023 | -131.47 Mn |
| Sep 30, 2023 | -55.47 Mn |
| Sep 30, 2023 | -55.47 Mn |
| Jun 30, 2023 | -91.48 Mn |
| Jun 30, 2023 | -91.48 Mn |
| Mar 31, 2023 | -134.94 Mn |
| Mar 31, 2023 | -134.94 Mn |
| Dec 31, 2022 | -28.82 Mn |
| Dec 31, 2022 | -28.82 Mn |
| Sep 30, 2022 | -69.53 Mn |
| Sep 30, 2022 | -69.53 Mn |
| Jun 30, 2022 | -1.06 Mn |
| Jun 30, 2022 | -1.06 Mn |
| Mar 31, 2022 | -66.57 Mn |
| Mar 31, 2022 | -66.57 Mn |
| Dec 31, 2021 | -156.27 Mn |
| Dec 31, 2021 | -156.27 Mn |
| Sep 30, 2021 | -33.11 Mn |
| Sep 30, 2021 | -33.11 Mn |
| Jun 30, 2021 | -44.09 Mn |
| Jun 30, 2021 | -44.09 Mn |
| Mar 31, 2021 | -11.38 Mn |
| Mar 31, 2021 | -11.38 Mn |
| Dec 31, 2020 | -196.75 Mn |
| Dec 31, 2020 | -196.75 Mn |
| Sep 30, 2020 | -57.28 Mn |
| Sep 30, 2020 | -57.28 Mn |
| Jun 30, 2020 | -56.89 Mn |
| Jun 30, 2020 | -56.89 Mn |
| Mar 31, 2020 | -45.80 Mn |
| Mar 31, 2020 | -45.80 Mn |
| Dec 31, 2019 | -59.99 Mn |
| Dec 31, 2019 | -59.99 Mn |
| Sep 30, 2019 | 19.95 Mn |
| Sep 30, 2019 | 19.95 Mn |
| Jun 30, 2019 | -38.77 Mn |
| Jun 30, 2019 | -38.77 Mn |